Here you will find all the news about our studies and the follow-up reports from ABCSG events

magazine of european medical 1/2024, Volume 17

The future of clinical trials – goals, ideas, and discussion


ABCSG opinion paper published in the latest issue of “memo”
magazine of european medical oncology 1/2024, Volume 17

In this state-of-the-art summary and opinion paper, we explore how improvements can be implemented into the current practice of clinical trial design, conduct, and reporting.

read more
Aktueller BIG-Newsletter

Latest Big-Newsletter reports on the ABCSG 63 / ERIKA Trial


ABCSG 63 / ERIKA (Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer) trial to start study recruitment in Q2 2024!

ABCSG 63 is an innovative, investigator-initiated trial in its final set-up phase, to be conducted in Austria and Germany under the academic sponsorship of ABCSG, and at approximately 18 trial sites with the recruitment target of 120 patients.

read more

First Site activated for Enrollment


On April 10th, the Pyhrn-Eisenwurzen Clinic Steyr (2nd Medical Department) under the lead of Principal Investigator Dr. Dieter Rossmann was activated as the first site of the ABCSG 62 / CAMBRIA-2 trial in Austria.

read more

UK Trade Commissioner and ABCSG Visit AstraZeneca: Focus on Breast Cancer Research


The ABCSG, represented by its President, Prof. Michael Gnant, was invited to a meeting with the British Trade Commissioner for Europe, Chris Barton, at the new Austrian headquarters of the Anglo-Swedish pharmaceutical company AstraZeneca on March 19.

read more
Assoc. Prof. Priv.-Doz. Dr. Georg Pfeiler

Researcher of the Month: Assoc. Prof. Dr. Georg Pfeiler


We would like to congratulate our colleague Assoc. Prof. Dr. Georg Pfeiler for the title “Researcher of the Month”, which was awarded to him by the Medical University of Vienna in the current issue of its magazine “MedUnique people” 01/March 2024.

read more

ABCSG 60 / CAMBRIA-1: Austrian Center GLOBAL Top Recruiting Site!


We are very proud that an Austrian center is the global top recruiting site this week with 17 randomized patients! Our cordial congratulations and thanks go to Dr. Daniel Egle and his team at the University Clinic for Gynecology Innsbruck.

read more
CDK4/6 inhibition in early breast cancer

The on-demand video of the webinar “CDK4/6 inhibition in early breast cancer – Recent data and controversies?” is now available!


The virtual continuing education event “CDK4/6 inhibition in early breast cancer – Recent data and controversies?” took place on Wednesday, November 8th, 2023 (05:30 – 07:00 pm, CET). A total of 104 participants from 13 countries participated in the webinar.

read more

Latest BIG newsletter reports on the ABCSG 52 / ATHENE study


Successful recruitment during COVID-19 pandemic and very promising trial results!

read more
Paradigm shift: a changing CDK4/6 inhibitor treatment landscape

The on-demand video of the webinar “Paradigm shift: a changing CDK4/6 inhibitor treatment landscape” is now online!


The virtual continuing education event “Paradigm shift: a changing CDK4/6 inhibitor treatment landscape” took place on Thursday, September 14th , 2023 (06:00 – 08:00 pm, CET). A total of 87 participants from 13 countries took part in the webinar.

read more
ABCSG-Präsident Prof. Michael Gnant zählt 2022 erneut zum Who is Who der globalen akademischen Forschungselite

ABCSG President Prof. Michael Gnant in 2022 once again among the who’s who of the global academic research elite


For the third time already, Austria’s internationally renowned cancer researcher Professor Michael Gnant, MD, FACS, FEBS has been named as one of the worldwide “Highly Cited Researchers 2022”.

read more
Univ. Prof. Dr. Michael Gnant

The Positive Impact of Disclosing “Negative” Research Results


For the Austrian Breast and Colorectal Cancer Study Group (ABCSG), the year 2021 showed how successful and thriving – and at times challenging – clinical research can be. From practice-changing study results to the positive impact and opportunities of disclosing negative trial outcome, Professor Michael Gnant, President of the ABCSG, provides insight into some ABCSG […]

read more

PALLAS 1st Call for Research Project Proposals – 15. Sep. 2021- 15. Jän. 2022


The first full scientific publication of PALLAS study data was made public in 2020 and subsequent publications are in preparations.

read more

First results of ABCSG 51 / AURORA study published


The AURORA program is dedicated to researching the molecular characteristics of locally recurrent / advanced and metastatic breast cancer not amenable to treatment with curative intent. For this purpose, the tumor and blood samples of participants are assessed for tumor heterogeneity, clonal evolution and transcriptional changes using high-throughput sequencing technologies (NGS). In addition, biomarkers of […]

read more

Share on